These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 10478579)

  • 1. Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome.
    Reuter I; Ellis CM; Ray Chaudhuri K
    Acta Neurol Scand; 1999 Sep; 100(3):163-7. PubMed ID: 10478579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement].
    Trenkwalder C; Boesch S; Ceballos-Baumann A; Dressler D; Eggert K; Gasser T; Honig H; Müller T; Reichmann H; Sieb JP; Storch A; Odin P; Poewe W
    Nervenarzt; 2008 Apr; 79(4):475-9. PubMed ID: 18210043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nocturnal subcutaneous apomorphine infusion for severe insomnia in Parkinson's disease.
    Garcia Ruiz PJ
    Mov Disord; 2006 May; 21(5):727-8. PubMed ID: 16547919
    [No Abstract]   [Full Text] [Related]  

  • 6. Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment.
    Priano L; Albani G; Brioschi A; Guastamacchia G; Calderoni S; Lopiano L; Rizzone M; Cavalli R; Gasco MR; Fraschini F; Bergamasco B; Mauro A
    Neurol Sci; 2003 Oct; 24(3):207-8. PubMed ID: 14598090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
    Colzi A; Turner K; Lees AJ
    J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial.
    Katzenschlager R; Poewe W; Rascol O; Trenkwalder C; Deuschl G; Chaudhuri KR; Henriksen T; van Laar T; Spivey K; Vel S; Staines H; Lees A
    Lancet Neurol; 2018 Sep; 17(9):749-759. PubMed ID: 30055903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous apomorphine in the treatment of Parkinson's disease.
    Frankel JP; Lees AJ; Kempster PA; Stern GM
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):96-101. PubMed ID: 2313313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Barbato L; Monge A; Nordera G; Ruggieri S
    Clin Neuropharmacol; 2003; 26(3):151-5. PubMed ID: 12782918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the Efficacy of Nocturnal Continuous Subcutaneous Apomorphine Infusion in Sleep Disorders in Advanced Parkinson's Disease: The APO-NIGHT Study.
    Fernández-Pajarín G; Sesar Á; Ares B; Castro A
    J Parkinsons Dis; 2016 Oct; 6(4):787-792. PubMed ID: 27662329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous subcutaneous apomorphine monotherapy in Parkinson's disease.
    Papuć E; Trzciniecka O; Rejdak K
    Ann Agric Environ Med; 2019 Mar; 26(1):133-137. PubMed ID: 30922043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
    Drapier S; Vérin M
    Rev Neurol (Paris); 2006 Oct; 162(10):1019-23. PubMed ID: 17028572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous subcutaneous apomorphine infusion in Parkinson's disease patients with cognitive dysfunction: A retrospective long-term follow-up study.
    Borgemeester RWK; van Laar T
    Parkinsonism Relat Disord; 2017 Dec; 45():33-38. PubMed ID: 29032012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion of apomorphine in patients with advanced Parkinson's disease and different degrees of functional disability.
    Salazar G; Martín J; Fragoso M; Font MA
    Neurologia; 2017; 32(6):407-410. PubMed ID: 26699210
    [No Abstract]   [Full Text] [Related]  

  • 16. Apomorphine: an underutilized therapy for Parkinson's disease.
    Poewe W; Wenning GK
    Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
    Martinez-Martin P; Reddy P; Katzenschlager R; Antonini A; Todorova A; Odin P; Henriksen T; Martin A; Calandrella D; Rizos A; Bryndum N; Glad A; Dafsari HS; Timmermann L; Ebersbach G; Kramberger MG; Samuel M; Wenzel K; Tomantschger V; Storch A; Reichmann H; Pirtosek Z; Trost M; Svenningsson P; Palhagen S; Volkmann J; Chaudhuri KR
    Mov Disord; 2015 Apr; 30(4):510-6. PubMed ID: 25382161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.
    Dewey RB; Hutton JT; LeWitt PA; Factor SA
    Arch Neurol; 2001 Sep; 58(9):1385-92. PubMed ID: 11559309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
    Henriksen T
    Neurodegener Dis Manag; 2014; 4(3):271-82. PubMed ID: 25095821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up.
    Pietz K; Hagell P; Odin P
    J Neurol Neurosurg Psychiatry; 1998 Nov; 65(5):709-16. PubMed ID: 9810943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.